INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Join Us at the SID Annual Meeting 2025 in San Diego!

Indero

Indero

Team of Experts

Author picture

We are excited to announce that our team will be attending the SID Annual Meeting this May. This is a fantastic opportunity to connect with industry leaders, explore the latest innovations, and discuss how we can collaborate to drive research advancement.

Dr. Jasmina Jankicevic, Indero’s Chief Medical and Scientific Officer, will also take the stage and present:

Balancing curiosity, relevance and feasibility in dermatology clinical research―May 9th, 7h AM (PDT)

  • Key clinical research considerations for investigations in dermatology
  • Crucial questions that require answers in different phases of clinical research in dermatology
  • Major obstacles to successful study design and implementation

Interactions and partnerships with industry―on May 7th at the 2025 Future Leaders’ retreat

  • Exploring the potential for advancements in the diagnostic and therapeutic dermatology drug & device innovation.

Book a meeting with us or visit us at Booth #26 to discuss true dermatology expertise!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >